目的 探討益心舒膠囊聯(lián)合替格瑞洛片治療急性心肌梗死的臨床療效。方法 選取2020年4月—2021年8月安陽市第三人民醫(yī)院收治的88例急性心肌梗死患者，根據(jù)隨機數(shù)字表法將所有患者分為對照組和治療組，各包括44例。對照組患者口服替格瑞洛片，90 mg/次，2次/d。治療組患者在對照組基礎上口服益心舒膠囊，1.2 g/次，3次/d。兩組在治療1個月后統(tǒng)計療效。觀察兩組臨床療效，比較兩組治療前后心功能指標、血小板聚集率、血栓指標。結(jié)果 治療后，治療組患者的總有效率（88.64%）比對照組（70.45%）高（P<0.05）。治療后，兩組的左心室射血分數(shù)（LVEF）、每搏輸出量（SV）明顯升高，二尖瓣舒張早期血流峰速度與二尖瓣環(huán)舒張早期運動峰速度之比（E/Em）顯著降低（P<0.05）；且治療后治療組的LVEF、SV高于對照組，E/Em低于對照組（P<0.05）。治療后，兩組的血小板聚集率顯著降低（P<0.05），且治療組血小板聚集率較對照組降低更明顯（P<0.05）。治療后，兩組的血漿凝血酶抗凝血酶復合物（TAT）、血栓調(diào)節(jié)蛋白（TM）、纖溶酶-α₂纖溶酶抑制物復合物（PIC）均顯著降低（P<0.05），且治療組的TAT、TM、PIC降低更明顯（P<0.05）。結(jié)論 益心舒膠囊聯(lián)合替格瑞洛片治療急性心肌梗死的療效確切，能提高心功能，降低血小板聚集率，調(diào)節(jié)血小板分泌，安全性良好。

Objective To investigate the clinical efficacy of Yixinshu Capsules combined with Ticagrelor Tablets in treatment of acute myocardial infarction. Methods Patients (90 cases) with acute myocardial infarction in Anyang Third People's Hospital from April 2020 to August 2021 were randomly divided into control and treatment groups, and each group had 44 cases. Patients in the control group were po administered with Ticagrelor Tablets, 90 mg/time, twice daily. Patients in the treatment group were po administered with Yixinshu Capsules on the basis of the control group, 1.2 g/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and cardiac function index, platelet aggregation rate, and thrombus index in two groups were compared. Results After treatment, the total effective rate of the treatment group (88.64%) was higher than that of the control group (70.45%) (P < 0.05). After treatment, the LVEF and SV in two groups were significantly increased, but the E/Em in two groups were significantly decreased (P < 0.05). After treatment, the LVEF and SV in the treatment group were higher than those in the control group, but the E/Em in the treatment group was lower than those in the control group (P < 0.05). After treatment, the platelet aggregation rate of two groups were significantly decreased (P < 0.05), and the platelet aggregation rate of the treatment group was significantly lower than that of the control group (P < 0.05). After treatment, the TAT, TM, and PIC of two groups were significantly decreased (P < 0.05), and the TAT, TM, and PIC of the treatment group were significantly lower than those of the control group (P< 0.05). Conclusion Yixinshu Capsules combined with Ticagrelor Tablets is effective in treatment of acute myocardial infarction, which can improve cardiac function, reduce platelet aggregation rate, and regulate platelet secretion, with good drug safety.

R972

河南省醫(yī)學科技攻關計劃（聯(lián)合共建）項目（LHGJ20191277）